Onconetix (ONCO) Income from Continuing Operations (2021 - 2026)
Onconetix (ONCO) posted quarterly Income from Continuing Operations of 4214875.0 for Q1 2026, up 50.68% year-over-year from 2797245.53 in Q1 2025, and down 174.33% quarter-over-quarter from 5670212.0 in Q4 2025.
Onconetix (ONCO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Income from Continuing Operations for 6 consecutive years, with 4214875.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 50.68% year-over-year to 4214875.0; the TTM figure through Mar 2026 stood at 9700807.0 (down 566.8% YoY), while the FY2025 annual figure was 14041646.0, down 2739.38% from the prior year.
- Income from Continuing Operations fell to 4214875.0 in Q1 2026 per ONCO's latest filing, from 5670212.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 28758149.0 in Q4 2024 and bottomed at 1653009294885.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 97239767265.06 across 5 years, with a median of 4914016.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 208641013.41% — and 2024, when it soared 230.44%.
- Onconetix's Income from Continuing Operations stood at 3916121.0 in 2022, then tumbled by 463.0% to 22047777.0 in 2023, then jumped by 230.44% to 28758149.0 in 2024, then tumbled by 80.28% to 5670212.0 in 2025, then plunged by 174.33% to 4214875.0 in 2026.
- Business Quant data shows ONCO's Income from Continuing Operations at 4214875.0 in Q1 2026, 5670212.0 in Q4 2025, and 8783702.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.87 Mn |
| Mar 31, 2026 | -4.21 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -2.37 Mn |
| Mar 31, 2025 | -8.55 Mn |
| Dec 31, 2024 | 28.76 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Jun 30, 2024 | -14.31 Mn |
| Mar 31, 2024 | -11.12 Mn |
| Dec 31, 2023 | -22.05 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -6.87 Mn |
| Mar 31, 2023 | -2.85 Mn |
| Dec 31, 2022 | -3.92 Mn |
| Sep 30, 2022 | -4.91 Mn |
| Jun 30, 2022 | -1,653.01 Bn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Sep 30, 2021 | -1.10 Mn |